Randomized comparative study of immediate CAB (combined androgen blockade) therapy and differed CAB therapy for stage B to D2 prostate cancer

Randomized comparative study of immediate CAB (combined androgen blockade) therapy and differed CAB therapy for stage B to D2 prostate cancer - Randomized comparative study of immediate CAB (combined androgen blockade) therapy and differed CAB therapy for prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015161

Enrollment

300

Registered

2014-09-15

Start date

2007-02-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

immediate MAB (CAB) therapy patients receive LH-RH agonist and bicaltamide from the biginning of endocrine therapy differed MAB (CAB) therapy patients receive LH-RH agonist only from the biginning o

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) pathologically confirmed prostate cancer 2) Patients who want to receive endocrine therapy 3) age from 20 years old, no upper limits 4) PS 0-1

Exclusion criteria

Exclusion criteria: 1) high ALP> x2.5 WNL 2)

Design outcomes

Primary

Measure	Time frame
Progression free survival, (time to progression (CRPC))	—

Countries

Japan

Contacts

Public ContactHidefumi Kinoshita

Kansai Medical University Department of Urology and Andrology

kinoshih@hirakata.kmu.ac.jp072-804-0101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026